##For the first time, Cao Bin, the head of the trial, revealed important information about ridgway

Wechat, bingdianweekly

Features, China Youth Daily's in depth reporting brand. We believe that news has more than one day of life.

The following article originated in the world of smoking, by Cao Bin and Wang Yimin

As a vertical new media platform for the discipline of aspiration in China, it is based on the integration of the resources of aspiration in all levels of hospitals and gradually enriches the authoritative information of aspiration, it provides authoritative web-based specialized information support for doctors of aspiration and critical care medicine and related disciplines, and endeavors to establish a national network of aspiration-based medical collaboration professional system, providing new media interaction and promotion services for the whole industry.

![img](data:image/jpeg;base64,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)
Professor Cao Bin. Photo / Xinhua view

[ editor's note ] after the outbreak of new crown pneumonia, Cao Bin, vice president of china-japan Friendship Hospital and special professor of "Changjiang Scholars Program" of the Ministry of Education, was the first group of experts appointed to Wuhan by the National Health Service.

At an online interview organized by the Chinese Medical Association and the Chinese Medical Association, he first introduced his experience in Wuhan to his colleague Dr. Wang Yimin, as well as the highly concerned and once-rumored "Miracle Drug" antiviral drug, Radhivir (report of the clinical trial of Radhivir pending results) , and the progress of the clinical trial of Lopelavir Litteau.

According to Cao Bin, they arrived in Wuhan on December 31 last year, and on January 1 this year, he and Li Xingwang, a doctor at Beijing Ditan Hospital, were among the first group of national experts, harvard Medical School and a team of experts in Wuhan Co authored the first version of the outbreak -- a treatment plan for the viral pneumonia of unknown causes in Wuhan (Trial Edition) , completed in the early hours of January 3. "This is the first edition of the protocol for this outbreak, which was finalized at 1:00 a.m. on January 3,2020. " (see previous report of the earliest version of the protocol in the freezing point weekly: White and green manuals: Changes in diagnostic criteria for new coronary pneumonia.)

"We have made it clear that patients who meet the definition of a disease should be concentrated in a medical facility with isolation conditions, " he said.

Regarding the antiviral treatment of NCP, Cao Bin also pointed out that more than a dozen autopsies of deceased patients were recently performed in Wuhan, and the most striking thing was the presence of large numbers of virus particles and inclusion bodies in the Alveoli and pulmonary Septa of the patients. "without removing the virus, can other treatments work? " Some patients have lung damage so severe that even with ECMO, it can not be reversed. All of these suggest that the most important part of treatment is to treat the disease, remove the disease, reduce the virus replication, and reduce the virus clearance time.

"I keep repeating viruses, viruses, viruses! The most important thing in treatment is antiviral, antiviral, antiviral! It's a very obvious logic. "

On the clinical trial of Radzivir, WHO Director General Senior Advisor Bruce Aylward said at a press conference held by the Joint China World Health Organization (WHO) expert team on February 24, ridgway "may have the desired effect" .

Cao Bin said in the interview, many leaders and colleagues have repeatedly "questioned" him about a clinical trial of Red Xiwei: "Dr. Cao, many hospital doctors can only observe a few, more than a dozen cases to see the effect. You have over 200 cases here, why don't you know the effect?"

This interview provides Cao Bin's detailed answer. The full text is published in China breathing discipline vertical new media platform "breathing" (click "read the original text" to view the interview video) , the Youth newspaper freezing point weekly authorized forwarding.

Note: This doctor to Doctor Interview has a reading threshold, but it's a lot of information.

* Very few patients have had seizures in the last week

Very few patients have been sick in the last week

Cao Bin: Let's start with the current situation in Wuhan. We are glad to see that a shelter hospital has begun to "retire" , indicating that no patients have been transferred to this shelter hospital. Moreover, according to the patients admitted by the medical team of the Chinese and Japanese hospitals, nearly 70 patients were admitted in the last week, and 26 patients were discharged. There are currently more than 40 patients in the unit, two of whom are intubated, one is tracheotomized, and one is on ECMO. From the point of view of the newly admitted patients, there are almost no cases with onset less than a week. Our Ward is in the sino-french Xincheng District of Wuhan Tongji Hospital. From what we have learned from the national medical team in other wards, the number of patients, including those in the Wuhan Union Hospital, has been very low in the last week. Today's inpatients, including the critically ill patients, are relatively long-term onset, for example, more than two weeks, more than 20 days of patients or there are many, I do not particularly know outside of Wuhan, but from what I've heard about the situation in Wuhan, the number of new patients is indeed declining, which is a very happy message.

Wang Yimin: listen to you to mention "the patient stays in the hospital for a long time" , is not that this part of the symptoms of the more serious patients into what we call the "tug of war" state?

Cao Bin: well, to be exact, our team has just calculated, that the median length of stay among survivors is 22 days, so that means that for critically ill or critically ill patients, they've all been in the hospital longer.

* The clinical trial of Litteau has been concluded

The clinical study of Litteau has been concluded

Wang Yimin: This time "block new crown, authority online" topic, please tell about "new drugs" in some things to be expected. I've been involved in a lot of your team's work, and you've been very concerned about the viral pneumonia in our country, not just this outbreak, do you think your previous clinical experience will be of great help in the treatment of this epidemic and in the development of new research?

Cao Bin: Thank you for asking. Our team is leading three clinical trials of a combination of drugs -- Harvard, Ritonavir, and Radicivir. Of these, the patients included in Ritonavir and Ridgeville 2 all met the criteria for severe and critical illness. First, let's look at what was the biggest difference in the design of the Ritonavir and Ridgway Studies?

The Ritonavir study was a prospective, randomized, controlled clinical trial. The people in the Ridgway 2 study were the same as those in the Ritonavir study, with severe and critically ill pneumonia, but with one difference. In the Ritonavir study, we did not set a time limit for patients to enter the group from the onset, and the design of the recently registered rydsiwe study at the NIH (National Institutes of Health) was similar to that of our earlier ropelavir Ritonavir study. But the design of the study was rigorous, and that's what we learned from the influenza virus -- as a doctor in infection, ICU, or aspiration, for mild flu, we require anti-flu drugs within 48 hours of onset. For severe flu, we can extend it to the fifth day of onset.

As I have just said, now some patients in Wuhan Hospital have been in hospital for more than 20 days. At this time, when they re-enter the group, if the patient is finally cured, dare I say it is because the antiviral drug works? So, when we did the design for Ridgeway 2, we got stuck on 12 days, and we were really torn between being stuck on 10 days or 12 days or 14 days? It's a tough call.

In addition, a third study was carried out on Radzivir 1, which studied patients with mild to moderate neocoronavirus pneumonia.

And I'm happy to report that our clinical study of Litteau is now officially closed. We completed a prospective, randomized, controlled clinical trial of 199 Ritonavir patients. A few days ago, the team presented the results of the Lopiravir Litteau clinical study to the relevant departments of the state in a comprehensive report. The Department of Science and Education of the National Health Commission organized an expert evaluation meeting. The experts present at the meeting spoke highly of our research. We hope that the results of such research will be known to the international community, including the WHO, as soon as possible. We also hope that the results of this study will serve as strong evidence-based medical evidence for the next edition of our diagnostic and therapeutic protocols.

Cao Bin: Why was our team able to conduct the design of such clinical trials, the registration of clinical studies, and the ethical approval of clinical studies? This is closely related to our accumulation of more than a decade, without which we would not have been able to come up with a more mature research programme in the face of a major epidemic. For the past decade or so, our entire team has been very focused on community acquired pneumonia, and very focused on adult community acquired viral pneumonia. In 2019, our team published a number of studies, one of which was to examine the viral profiles of adult community acquired pneumonia, especially viral pneumonia, in 13 provinces of China, the incidence, severity and prognosis of influenza virus pneumonia and non-influenza virus pneumonia were analyzed.

And I want to tell you that in the case of severe influenza, our team is now leading a number of studies on severe influenza, including the treatment of severe influenza in combination with Favipiravir and Oseltamivir, this included a comparison of the severity of severe influenza a and severe influenza B. The lead author of the two studies, both by Dr. yeaming Wang, was published last year in Jid and Open Forum Infdis, respectively.

Cao Bin: Why do I want to talk about these two studies of severe influenza? Because in both studies, we determined which end point we should use in the viral pneumonia. Because for a prospective, randomized, double-blind, controlled study, two factors are important. First, determine what the primary endpoint is, because the primary endpoint determines how many samples need to be selected. Second, what is the study population? In fact, on January 1,2020, director Li Xingwang and I, as the first group of national experts, together with relevant experts from Wuhan, wrote a diagnosis and treatment plan for the Wuhan area, as the cause of the disease was not yet clear at that time, so this version of the diagnosis and treatment program name is "Wuhan unknown reason viral pneumonia diagnosis and treatment program (trial version) . ". This is the first version of the guidelines for this outbreak, which were finalized at 1 a.m. on January 3,2020. In this version of the guidelines, we have made it very clear what is mild to moderate pneumonia and what is severe pneumonia. What are the criteria by which we judge mild to moderate pneumonia and severe pneumonia? That's what we used to know in studies of severe influenza pneumonia. Over the past few years, these definitions have been applied very well and expertly in our experience with severe influenza. "Wuhan's viral pneumonia for unknown reasons (trial version) " actually provided a blueprint for a later series of national "COVID-19 pneumonia diagnosis and treatment" . In "Wuhan's viral pneumonia for unknown reasons (trial version) " , we explicitly proposed to centralize patients who meet the definition of disease in medical institutions with isolation conditions.

To recap our end point, the Lopelavir Litteau clinical trial uses a 7-point composite end point, and in fact more and more clinical trials are now focusing on the composite end point. The clinician may see patients who have been unable to disengage from the endotracheal tube for a long time, or who have disengaged from the breathing machine but can not leave the hospital without oxygen, or who have disengaged from oxygen but can not leave the hospital for a variety of reasons, still Hospitalized; and, how can we quantify complex clinical outcomes when patients are discharged but do not return to a normal life? This requires composite endpoints. In fact, it's not just acute respiratory infections that use multiple study endpoints. When we read the literature, we found that they also use these multiple endpoints for "prognostic judgments of stroke. ".

To give you a very simple example, a patient suffered a stroke, the best outcome is first Hemiplegia, Aphasia and slowly return to a completely normal state, this is the best case; But some of the most severe cases are brain hernias that occur after a stroke and die quickly; others are in a coma so severe that they can not communicate with their families at all, as if they were in a vegetative state; and still others become hemiplegic after a stroke, unable to take care of themselves; some stroke, although also Hemiplegia, but can take care of themselves, daily activities are not limited..

In other words, when studying stroke, it's hard to know whether a patient will simply herniate and die after a stroke, so the prognosis is not well understood. By the same token, in severe influenza virus pneumonia, as well as in this severe new coronavirus pneumonia, we used a compound end point index, which we used in the Lopelavir Ritonavir study, later, I saw a lot of follow-up studies in China, have followed or referred to our design of this research endpoint.

![img](data:image/jpeg;base64,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)

* February 31 to Wuhan, January 1 to write the diagnosis and Treatment Program, January 3 finished in the early morning

December 31 to Wuhan, January 1 to write the diagnosis and Treatment Program, January 3 finished in the early morning

Wang Yimin: one of the first things I'm concerned about, and one of the things that a lot of internet users are concerned about, is that there are many different types of clinical studies -- why are all three of your top three studies focused on drugs? We would like you to give us an overview of the research background and design ideas for each study.

Cao Bin: I arrived in Wuhan on December 31,2019, as one of the first members of the national expert group. I arrived in Wuhan at 2:00 pm. I stayed for a short time at the Wuhan Health and Health Commission. Then the expert group was divided into two groups, one was a clinical expert group, the other is to CDC epidemiologist-based, to the South China Seafood Market for epidemiological investigation. Our clinical expert group's Place of work is in Wuhan Gold Silver Pool Hospital.

Two days before we arrived in Wuhan, around December 29, a number of hospitals in Wuhan admitted symptoms, signs and laboratory tests for similar diseases were successively transferred to Jinyintan Hospital, so our first group of experts to work on the battlefield in the Golden Pool Hospital. In Icu Ward Round, we discussed each patient, and Wuhan Expert Group together after communication, we have a very strong impression, what is the impression?

Cao Bin: All the patients we saw had the same symptoms, including fever, dyspnoea, dry cough, no sputum, dyspnoea in severe cases, and Ards, some with Acute respiratory distress syndrome symptoms, it's a clinical manifestation. There are also radiographs, which are strikingly similar: Multiple ground-glass infiltrations of both lungs, partial consolidation, mild to severe, possibly hypoxic, severe respiratory failure, and, the patients had a number of common laboratory features: normal or low white blood cells, especially lymphocyte. On our first day in Wuhan, we and the Wuhan Expert Group had made a very detailed description of the clinical features of these patients.

These features appear in Wuhan's viral pneumonia for unknown reasons (trial version) , and in fact our version came out very quickly. New Year's day we began to write, January 3 in the early hours of the formal completion of the draft, which is China's first version of the origin of the diagnosis and treatment program. Why did we say these patients were viral pneumonia for unknown reasons? Because of his performance, for an adult, the differential diagnosis of viral pneumonia, we first need to see if the diagnosis is valid, whether it is pneumonia. Second, what is the severity of the condition? And third, very important, is that we have a six-step approach to adult community-acquired pneumonia, and the third step is to speculate about possible pathogens. It wasn't just me, it was the infectious disease experts, the head of the smoking department at Wuhan Hospitals, who had focused the group on the viral pneumonia. It wasn't like a bacterial pneumonia, none of the patients had a PCT greater than 0.1 ngml, which could not be explained by bacterial pneumonia. Our Common Mycoplasma PNEUMONIAE PNEUMONIA, chlamydia pneumonia, legionella pneumonia are not such performance.

So, although there was no definitive etiological evidence at the time, everyone was pretty sure it was viral pneumonia. Of course, it would be wrong to say that we did not know any clues about virology. Everyone knows now that before we arrived in Wuhan at that time, several patients had already sent out NGS. NGS had already issued some reports, some reports directly reported SARS, some reports said it was similar to coronavirus, so we also received such information when we came to Wuhan, combined with the clinical manifestations of this group of patients is particularly typical of viral pneumonia, combined with this incomplete information we have, our knowledge of these patients is locked in the "viral pneumonia" , and it is assumed that it is most likely a coronavirus-induced pneumonia, this was the impression we shared with the Wuhan panel at the time.

* However, to use a second-line treatment of AIDS drugs to treat these patients, many doctors do not understand

Suddenly proposed to use a second-line treatment of AIDS drugs to treat these patients, many doctors do not understand

Cao Bin: For an infectious disease, oxygen therapy, breathing machines, including nutritional support therapy, including water electrolyte balance, including prophylactic antibiotics, and hormones recommended by some doctors, are all complementary. What's the bottom line? The most fundamental is the treatment of cause. Searching the literature, we found that during the SARS period, especially in the latter half of the SARS period, after April 2003, academician Yuen Kwok-yung's team of the University of Hong Kong had conducted in vitro studies on the SARS coronavirus, and found that both drugs were effective against the SARS coronavirus in the antiviral drug, one is Ritonavir and the other is interferon.

In 2003, doctors in Hong Kong combined the two drugs to treat the SARS coronavirus, but there was no condition for an RCT study because it was already in the late stages of SARS. They treated only 41 cases of SARS, compared with patients who had not previously been treated with Lopelavir or Ritonavir, death and respiratory failure rates were significantly lower in the Ritonavir group. That gives us a lot of confidence. And a few years ago, when South Korea's imported Middle East Respiratory Syndrome (Mers) caused an outbreak in the hospital, they used the same Ropelavir Litteau regimen. Ritonavir is a protease inhibitor that was first used to treat HIV infection. In fact, we identified the drug on December 31,2019. However, there are two issues at that time we are not sure: First, the pathogen is not coronavirus? We don't know. We can only guess. Second, even in the case of a coronavirus infection, there is no indication that the drug, Lopelavir Ritonavir, can treat COVID-19. We also reported the situation to the head of the National Health Commission's medical and health administration, who told us that Ritonavir could not be used directly in the clinic, but could be used in a clinical research design, it's perfectly reasonable.

We have also fully communicated this idea with President Zhang Dingyu of the Golden Pool Hospital. After careful discussion of the literature and evidence we have obtained with him, President Zhang Dingyu is very supportive. And we were very fortunate, that we had a GCP team at Golden Pond, so they had a basis for doing clinical research, and we've been working closely ever since.

Early on, we didn't immediately start randomizing groups. Because doctors did not have the experience of using Ritonavir when the etiology was unknown. At the time, doctors were also using antiviral drugs to treat viral pneumonia, and one could have guessed which drugs to use: one was Ganciclovir, the other was Oseltamivir. The two drugs are used in combination. Now, you might laugh at the treatment as silly, but at the time, with the etiology unclear and the viral pneumonia in mind, many doctors in Wuhan had no choice but to do so.

Although I tell you that Oseltamivir in combination with Ganciclovir did not work, when we suddenly came up with the use of Ritonavir, it was as if a second line drug for HIV was being used to treat these patients, a lot of doctors don't understand, don't agree, there's a lot of resistance. Before we started the RCT study, we looked at about 20 cases, and some doctors reported that the drug worked! But this is an isolated case, which means there are only twenty cases. The Lopiravir Ritonavir story is also known, and was once touted as a "Miracle Cure, " but that was after we launched the RCT. In the early days, even when we first looked at more than 20 cases, and some of the doctors said it worked, we didn't dare say, "This drug might be effective. ". We started the RCT study very rigorously and patiently, and our first patient was admitted on January 18, a week or so from January 9 through the ethics committee to January 18, we followed more than 20 patients in succession, but did not initiate a randomized study. We officially started the randomized study on January 18,2020, which is a starting point for our Lopiravi<per_0> clinical study. As of March 1,2020, our Lopelavir Litteau clinical trial included 199 patients, our follow up date was 28 days after randomization, and the last day of follow up for the last patient has now ended, we have also officially reported our findings to the state.

Wang Yimin: I just heard a point that at that time in the SARS study, academician Yuen Kwok-yung was the Lopelavir Ritonavir Interferon, because some people did not know the Lopelavir Ritonavir Research Program, (unlike ridgeway, who has seen the study online) , could you tell us more about these two randomized control groups, and whether or not they were simply using Ritonavir? Has Interferon been added? Is there a placebo?

Cao Bin: We actually started with the Hong Kong study  This includes fever, because these patients already have symptoms of fever, and if interferon is used again, it may affect our observation of the patient's symptoms. We initially discussed the use of a combination therapy such as Lopelavir and Ritonavir plus inhaled interferon as compared with the standard treatment group, but found a problem in more than 20 cases before we enrolled them immediately, inhaled Interferon, first of all, these patients live in isolation wards, which means a lot more work for the nurses in isolation wards, and second of all, there's an increased risk of aerosol production. Again, after observing the patient inhaled Interferon Airway response is relatively large, the occurrence of adverse reactions of airway stimulation, so when we started the RCT study, we revised the research program: divided into two groups, one is the standard treatment group, in accordance with national guidelines for diagnosis and treatment, the other group added Lopelavir and Ritonavir because, unlike later, we couldn't prepare for very careful clinical studies, we didn't have the conditions, we didn't have the placebo control, but what I want to explain to you is that our researchers, including the GCP teachers, don't know about clinical end-point evaluations.

And I'm happy to tell you that because we did it strictly at random, the equilibrium was very good for both groups, and the median age for both groups was 58. The sex ratio, underlying diseases, laboratory tests at the time of enrollment, and the severity of these patients'conditions, as well as the intervention drugs (including hormones) used by these patients after enrollment, were also matched. In this context, the only difference between the two groups is that one group has a Lopiravir Ritonavir, so we can compare them with confidence, did Litteau have any effect on severe new coronavirus pneumonia? How many adverse reactions were there after treatment with Lopelavir Ritonavir? The two most important questions we need to answer, first, is it working or not, and second, what are the side effects? How bad are the side effects? Any fatal side effects? That's something we need to think about.

Wang Yimin: some time ago, you have seen and heard the results of the Lopiravir Ritonavir study reviewed by Professor Lu Hongzhou of the Shanghai Public Health Center, the design of the study, the outcome of the study, and the number of patients observed in the study were all quite different, so there may be differences in the results of the study, but we must not make such a horizontal comparison, to see how that outcome, how this outcome... we must be objective about the conclusions of clinical research.

![img](data:image/jpeg;base64,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)
Professor Cao Bin. Photo / National New Office website

* What choice, Riddick

Why Ridgeway

Wang Yimin: Let's talk about the drug "Ridgeville" that everyone is very concerned about. I heard you just now. In fact, the research team has also been concerned about this drug for a very long time, it also comes from a drug that we screened out earlier, which may be effective. The research design, ethical review and so on were carried out at the first time. Please introduce it again. Thank you.

Cao Bin: the drug came into our field of vision after Ritonavir, in early January 2020, before I left Wuhan on January 9, I had our second target in Radzivir, because it just so happens, that there was an article just published online in Nature Communication, in which a team of doctors at the Chapel Hill School of Medicine in North Carolina, in the United States, tried to infect mice with MERS coronavirus, and in animal experiments, they looked at two drugs, one was ritonavir + Interferon, the same treatment for SARS and Mers, and two, we were very surprised to see that they also tested another drug, which is now officially known as Ridgway, so you can see that our team's tracking literature is very, very timely.

In this study, we were also surprised to see that in an animal model of MERS coronavirus, Ritonavir + interferon protected mice, reduced lung damage, and reduced mortality in mice, but when the researchers looked at how much the virus dropped, they found no statistical difference. But we also saw that ridgeway also protected mice, also reduced lung damage, and also reduced mortality in mice. Moreover, the ability of Ridgeville to reduce the titer of the virus was significant. This gives us a very big shock, that is to say, whether it is SARS, or Mers, at least in animal models, they used the Lopelavir Ritonavir + Interferon program is far less effective than Radzivir, and we're curious to see if ridgeway stays on the level of animal testing? As a result, we were fortunate to discover that the drug had just been published in the November 2019 issue of the Journal The New England Journal of Medicine. The human study, of course, is not the coronavirus, but the west African "Zaire ebolavirus. ".

This study at least gives us some confidence that, at least, the drug has been tested in people in Africa, and at least we can see the safety data in the African population. That's the story of how we locked in on Riddick after Ritonavir!

Wang Yimin: Can I put it this way, because a lot of people on the Internet are very concerned, about whether a drug is effective and whether it's safe, these are two important things, in terms of whether it's effective or not, you used the first article to find that the activity in vitro was very good, while the safety issue, although the Zaire ebolavirus application Ridgeville did not see such a good positive result, but at least you just mentioned the "safety. ". This is the conclusion we can draw from the second paper.

Cao Bin: yeah, so it's very fortunate that we have both evidence of the effectiveness of animal testing, and we have data on the safety of Ridgeway in human trials, so that gives us a lot of confidence, that led us to contact the clinical trial of Radzivir in China.

Wang Yimin: I have summed up some of the issues that people are more concerned about. In fact, there is a problem. When you first introduced our research, you told us about the "end" . Many experts are also concerned about why this mild illness, the clinical outcome we chose was the time of clinical recovery, rather than the "mild to severe" process that everyone was concerned about? And the clinical outcome of severe cases, as you just explained, we use a composite outcome index, there is no selected case-fatality rate, can you explain to us again, the clinical outcome of mild cases of choice is based on what considerations?

Cao Bin: Because mild cases are mostly self limited, because even with the new coronavirus, you see Wuhan has a high mortality rate, but for such a new outbreak of viral disease, most of it is self limited, so we have a completely different design for people with mild to moderate disease than we do for people with severe disease. In fact, these are two completely different clinical studies. For severe new coronary pneumonia, we are concerned about its "hard end" , that is, it can cause death and disability in patients, and of course death is one of our hard end points, but not all of them. In Our case-control study, we included a 28-day mortality in our composite end-point index, but why wouldn't we use the 28-day mortality? Because if we want to make a statistical difference, if we take the 28-day case fatality rate, the sample size is very large. And we didn't know what the case fatality rate was at first, so we couldn't calculate the sample size. And our composite end point, we have at least a foundation for severe influenza, and we have a foundation to help us calculate a reasonable sample size, which is very important.

For mild cases, we certainly do not rule out the possibility that a very small number of mild cases will eventually turn into severe cases, but from the law of the disease, more than 85% of the patients are self-limiting disease. If you want to solve the scientific problem of how to reduce the transition from mild to severe illness, I think you have to know which patients can be converted to severe illness and identify patients with severe risk factors, and then we're going to use this population as a study subject. You have to meet two criteria, rule number one, mild pneumonia, rule number two, and you also have a risk factor for severe illness, and the only time you can do that, the end point, the design, would be the number of people who had a mild to severe illness, otherwise 85 percent of patients would be self limited, and it would be virtually impossible to make that small difference.

Wang Yimin: I'm sure you can understand that the result of our study or the accumulation is from the summary and design of a large number of previous clinical studies and literature reading. I hope you can also understand our set of clinical outcomes. In fact, on the Internet, we also saw the news that on February 21, you also mentioned that a research institute under the NIH in the United States has also started a study on Ridgeville. The results of this RCT study are slightly different from ours, they mention one thing: there will be a mid-term analysis of the results, allowing for adjustments to the Control Group's interventions. For example, this drug was particularly effective, and I adapted it to a control group in the mid-term, as a trial to see if other drugs could be equally effective. What do you think of the difference between our plan and the American plan?

Cao Bin: I think there's essentially no difference. In fact, in our study of Ridgway 2, there is also a research design for mid-term analysis, which is not analyzed by researchers, but is analyzed by an independent security committee or data management committee, and there are five members of our Independent Committee for Clinical Research in Ridgway, two of whom are domestic experts and three of whom are foreign experts, including one from the United States, one from Canada and one from the United Kingdom, three of the five experts are statistical and the other two are clinical experts who look at our data from behind the scenes and judge it. And not just in the medium term, they were able to systematically review the progress of the program and see the difference in efficacy between the two groups in real time, even though it was actually a randomized placebo controlled double blind, but its effects are likely to be "more and more discrete, " and if the drug is effective, the dispersion will become more and more apparent.

Wang Yimin: Can I understand that it is either very effective or very harmful?

Cao Bin: There are three possibilities. One is that the adverse drug reaction causes accidental death, so the mortality rate will increase. The other is that the active drug is effective and the mortality rate will decrease. But the difference would have to be seen in the background by the Independent Commission when a certain number of selected cases accumulated. A third possibility is that, in addition to being effective and harmful, there is a possibility that the active drug will have no additional effect on standard treatment.

When a node is reached, the Independent Committee may call off the experiment. If it's an active drug, and it works, the trial stops, and all the patients are advised to take it. If the other case, the side effects are particularly large, but also must stop the experiment, the drug was "shot" off, the future will not allow the drug in the human body to carry out clinical research.

* Doctor, many hospital doctors can see the effect only by observing a few or a dozen cases. You have over 200 cases here. Why don't you know the effect?

Doctor Cao, many doctors in hospitals can see the effect only by observing a few cases and a dozen cases. You have over 200 cases here. Why don't you know the effect?

Wang Yimin: Although we don't know the final result at present, could there be some information that could "reveal" to us?

Cao Bin: We now have more than 230 studies of Ridgway 2 that have reached the sample size required for the mid-term analysis, but reaching the sample size and being able to do the mid-term analysis are completely different concepts, and why is that? Because inclusion doesn't mean we can evaluate, we need another 28 days of follow-up, and it certainly doesn't mean it has to be 28 days, because our end point is "as long as we reach a clinical outcome, " we can evaluate. So, as researchers, we look forward to seeing whether or not a node can emerge when more than 230 patients reach a clinical outcome? This node would allow the independent safety committee to make an objective, scientific assessment, and if that were to happen, we wouldn't need to enroll 453 patients, we could enroll 400 or 300.

Wang Yimin: Many doctors in front-line hospitals will say that when they are managing patients, the changes in patients'conditions cause difficulties in making decisions. What drugs should be added or subtracted? In making that decision, he hopes clinical studies will answer those questions. But now clinical research does not involve these special special details of the clinical problems, how should we look at this matter?

Cao Bin: it actually means "how to understand both clinical research and clinical work. " . My understanding is that clinical research is actually clinical work, but in clinical research work, there are strict limits on whether research drugs can be used or not, it also limited the control group, or all groups, to a standard protocol. I think for any doctor to participate in a clinical study, you have to make a commitment to "follow the standard, " which limits the number of specific prescriptions and treatments that the clinician can prescribe, these personalized prescriptions are often short of evidence based medicine. I'M NOT OPPOSED TO INCORPORATING evidence-based medicine into clinical practice, but if it's unproven, if you're going to be in a clinical trial, it has to be standard, the excessive use of unproven treatments or medications is not permitted.

I would also like to explain that in the last two months, many leaders and colleagues have repeatedly "questioned" me: Dr. Cao, many hospital doctors can only observe a few, more than a dozen cases to see the effect. You have over 200 cases here. Why don't you know the effect?

I think it's a difficult question to answer, as I just explained to you about Ritonavir, we actually looked at 20 cases before the RCT, and some of them were effective, but if we looked at 20 cases, it's probably ineffective again. Therefore, prospective randomized controlled studies are necessary to answer questions about the efficacy of each therapy. "Dr. Cao, aren't you stupid? " Someone might ask. "Why didn't you say something when you found out in early January that Lopelavir Ritonavir was effective on some patients? "

Wang Yimin: Can I understand that this is because many doctors in the front line don't actually have much experience in clinical research, or even lack some training in clinical research and thinking, they are better at seeing patients, treating patients with drugs, and have limited experience of actually participating in clinical research. In your answer to this question, could you tell me what "qualities" are necessary for clinical research? It may be a little different from seeing a patient or treating a patient.

Cao Bin: Thank you for your question. As I said earlier, why were we able to target Ropiravir and Ritonavir? Just because read a book, read the literature, if not read a book, Do not read the literature, then how can we know there are two drugs in the world? I think that's the first step.

The second requirement is "need to doubt" , must not hear that a drug effective, dare to patients for general clinical application. For a man with medical training, it's a terrible thing to take drugs. In addition, we in the medical students, training and education of doctors, often repeat the thing, is that "long hours do not represent experience. ". In fact, the accumulation of our experience must be built on the basis of evidence. Because we specialize in pneumonia, for example, a medical team sees 100 patients a month, and how many of those 100 patients can really tell the story? Is the etiology clear? Is the patient as well treated as expected based on the results of the Antimicrobial Susceptibility Test? And is the clinical manifestation consistent with our grasp of the Basic Law?

Of the 100 patients we've seen in the clinic, the ones we can actually get evidence-based medicine from, I don't think it's more than double-or even single-digit. In the hospital with strong ability of etiological diagnosis, it may reach 20 or 30, but in some hospitals I think it may be 0. But we must not because the hospital where the ability to diagnose pathogens is relatively weak, not to pursue the etiology of diagnosis, which is completely wrong! Even if only one in 100 patients a month had evidence-based medical evidence, it would be a very valuable experience. One patient is experience, and you're not going to get any valuable experience managing 99 other patients, and you're probably going to take the wrong experience and you're going to hurt your next patient even more.

I am a little excited to mention this, just mentioned the "quality" , I think it has nothing to do with the quality, it is just the usual habits and attitudes when managing patients, you read or not, you will directly decide whether you will be affected by bad information. As clinicians, we've talked about the importance of reading, of being skeptical, of being able to make your own judgments. Finally, the accumulation of experience, must be based on evidence, no evidence, talk about what experience?

Wang Yimin: Let's ask Professor Cao to summarize our topic today.

Cao Bin: Again, for Covid-19, antiviral treatment is the most important thing, whether it's mild or severe. Without treatment and intervention for the cause of the disease, other treatments are very passive, so everyone in the work, we must do everything possible to suppress the virus.

In fact, what we have now observed is this: the presence and detoxification time of coronavirus in the body is very long, and more than a dozen autopsies have recently been performed in Wuhan, the most shocking is the patient's Alveolar cavity, the large number of Pulmonary Septum virus particles and virus inclusion body. Imagine a critically ill patient lying in bed with a lung full of virus particles, a large number of virus particles in the electron microscope can be seen very typical of the corolla-shaped virus particles, the virus does not get rid of the other treatment can work? In addition, the hormone is also secondary, the patient's inflammatory performance is due to the virus to stimulate the excessive inflammatory performance of the virus, not to remove the virus, only with immunosuppressive drugs, can it work?

Breathing support is a great tool to allow patients to gain valuable recovery time. But not everyone is so lucky. Some patients have lung damage so severe that even an ECMO can not reverse it. This is to remind us that etiological treatment, remove the cause of disease, reduce virus replication, reduce the virus clearance time is the most important part of treatment!

The pathophysiology of the disease is "viral pneumonia" and "systemic inflammatory response to viral pneumonia, " and we see a lot of critically ill patients go into shock, but in fact, he doesn't have a bacterial infection, but is only the pure virus infection, therefore, I repeatedly stressed the virus, the virus, the virus! The most important treatment is antiviral, antiviral, antiviral! This is a very obvious logical relationship.

Wang Yimin: Thank you, Professor Cao. The idea that he instilled in us, reminded me of a word that we've always used in clinical practice, must be "science" , and the second is "protocol. ". What we're doing must be the most "scientific" of things. Although there are still some unresolved, unknown topics, we are facing the virus is unknown, but we must use the scientific attitude to face it, with scientific weapons to defeat it. What are the rules? The discipline comes from our clinical training every day, from the hard work of every clinical study, from the accumulated results of you or your team, it certainly does not take a day to do a study of Ropelavir, Ritonavir, and Ridgway, nor does it take a day to get a clear idea of the nature of the viral pneumonia, again emphasizing that "experience must come from the accumulation of time" .

So I want you to feel what Professor Cao Bin has taught you: that fighting the virus is important, but that doesn't mean that other support isn't important, that we have to prioritize, that we have rules about how we think about disease in science at this stage, i hope you feel the same way as I do, and I hope you will be patient while we show the clinical results of Ridgeway.

Produced by China Youth Daily

If you think it looks good, click here

Go to "discover"-"take a look" browse "friends watching"

Sent

####Send it to take a look

Sending

A scan of wechat
Pay attention to the account


-------------
title: For the first time, Cao Bin, the head of the trial, revealed important information about ridgway
source: FREEZING POINT
authors: _
editors: _
proofreader: _
photographer: _
translator: _
via: https://github.com/2019ncovmemory/nCovMemory
link: https://mp.weixin.qq.com/s/YCtX2xyylAfryCs63rLk2g
archive: https://archive.li/4DVYw
snapshot: https://github.com/2019ncovmemory/nCovMemory/blob/master/archive/jpg/3066.jpg
lead: "How did the antiviral therapy for NCP work? "
cover: data:image/jpeg;base64,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
